DE10220230A1 - Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms - Google Patents
Verwendung von Rotigotine zur Behandlung des Restless Leg SyndromsInfo
- Publication number
- DE10220230A1 DE10220230A1 DE10220230A DE10220230A DE10220230A1 DE 10220230 A1 DE10220230 A1 DE 10220230A1 DE 10220230 A DE10220230 A DE 10220230A DE 10220230 A DE10220230 A DE 10220230A DE 10220230 A1 DE10220230 A1 DE 10220230A1
- Authority
- DE
- Germany
- Prior art keywords
- acrylate
- tetrahydro
- thienyl
- ethyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000005793 Restless legs syndrome Diseases 0.000 title claims abstract description 56
- 229960003179 rotigotine Drugs 0.000 title claims description 22
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 21
- 239000000902 placebo Substances 0.000 claims abstract description 13
- 229940068196 placebo Drugs 0.000 claims abstract description 13
- 230000006872 improvement Effects 0.000 claims abstract description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000853 adhesive Substances 0.000 claims description 32
- 239000011159 matrix material Substances 0.000 claims description 30
- 230000001070 adhesive effect Effects 0.000 claims description 29
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 17
- 229940100640 transdermal system Drugs 0.000 claims description 17
- KFQYTPMOWPVWEJ-UHFFFAOYSA-N 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 KFQYTPMOWPVWEJ-UHFFFAOYSA-N 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- 239000013464 silicone adhesive Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 239000012458 free base Substances 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- -1 hexyl methyl Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 7
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229910052909 inorganic silicate Inorganic materials 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- CEXBONHIOKGWNU-NTISSMGPSA-N hydron;(6s)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound [Cl-].CCC[NH+]([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 CEXBONHIOKGWNU-NTISSMGPSA-N 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 4
- 229940055577 oleyl alcohol Drugs 0.000 claims description 4
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 150000003505 terpenes Chemical class 0.000 claims description 4
- 235000007586 terpenes Nutrition 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 235000019795 sodium metasilicate Nutrition 0.000 claims description 3
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 claims description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical class CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 2
- BLCTWBJQROOONQ-UHFFFAOYSA-N ethenyl prop-2-enoate Chemical compound C=COC(=O)C=C BLCTWBJQROOONQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 150000002314 glycerols Chemical class 0.000 claims description 2
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 claims description 2
- 229940065472 octyl acrylate Drugs 0.000 claims description 2
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229910052913 potassium silicate Inorganic materials 0.000 claims description 2
- 235000019353 potassium silicate Nutrition 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 238000009097 single-agent therapy Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- 229920006267 polyester film Polymers 0.000 description 5
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
- 206010038743 Restlessness Diseases 0.000 description 4
- 229940052760 dopamine agonists Drugs 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 229920000058 polyacrylate Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920003149 Eudragit® E 100 Polymers 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229920003082 Povidone K 90 Polymers 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 238000011294 monotherapeutic Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229960003089 pramipexole Drugs 0.000 description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010040981 Sleep attacks Diseases 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- ZJQPLBFKBQYYIO-UHFFFAOYSA-N dodecasodium;trisilicate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] ZJQPLBFKBQYYIO-UHFFFAOYSA-N 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- CEXBONHIOKGWNU-UHFFFAOYSA-N hydron;6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound Cl.C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 CEXBONHIOKGWNU-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XJSMBWUHHJFJFV-VTIMJTGVSA-N α-dihydroergocryptine Chemical compound C([C@H]1N(C)C2)C([C]34)=CN=C4C=CC=C3[C@H]1C[C@H]2C(=O)N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3CCC[C@H]3[C@]2(O)O1 XJSMBWUHHJFJFV-VTIMJTGVSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10220230A DE10220230A1 (de) | 2002-05-06 | 2002-05-06 | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| US10/429,283 US20040048779A1 (en) | 2002-05-06 | 2003-05-02 | Use of rotigotine for treating the restless leg syndrome |
| RU2004131866/15A RU2301063C9 (ru) | 2002-05-06 | 2003-05-05 | Форма для трансэпикутанного введения для лечения синдрома усталых ног |
| CA2787384A CA2787384A1 (en) | 2002-05-06 | 2003-05-05 | Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome |
| EP03727432A EP1501499B1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
| HK05105199.3A HK1072541B (en) | 2002-05-06 | 2003-05-05 | Trans-epicutaneous administration form for treating restless leg syndrome |
| IL16486103A IL164861A0 (en) | 2002-05-06 | 2003-05-05 | Trans-epicutaneous administration form for treating restless leg syndrome |
| PT03727432T PT1501499E (pt) | 2002-05-06 | 2003-05-05 | Forma de administração trans-epicutânea para tratamento da síndroma das pernas inquietas |
| AU2003233233A AU2003233233B2 (en) | 2002-05-06 | 2003-05-05 | Trans-epicutaneous administration form for treating restless leg syndrome |
| CNB038160250A CN100396281C (zh) | 2002-05-06 | 2003-05-05 | 治疗不宁腿综合症的经皮给药方式 |
| KR10-2004-7017685A KR20040104697A (ko) | 2002-05-06 | 2003-05-05 | 하지불안증후군 치료용 경피투여 형태 |
| DE50309318T DE50309318D1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
| NZ536533A NZ536533A (en) | 2002-05-06 | 2003-05-05 | Trans-epicutaneous administration form for treating restless leg syndrome |
| MXPA04010687A MXPA04010687A (es) | 2002-05-06 | 2003-05-05 | Forma de administracion transepicutanea para tratar sindrome de pierna temblorosa. |
| UA20041109078A UA81625C2 (ru) | 2002-05-06 | 2003-05-05 | Применение ротиготина для трансепикутального лечения синдрома уставших ног |
| SI200331195T SI1501499T1 (sl) | 2002-05-06 | 2003-05-05 | Oblika za transepikutano dajanje za zdravljenje sindroma nemirnih nog |
| BR0309837-0A BR0309837A (pt) | 2002-05-06 | 2003-05-05 | Forma de administração trans-epicutânea para tratamento da sìndrome das pernas inquietas |
| ES03727432T ES2301795T3 (es) | 2002-05-06 | 2003-05-05 | Forma de administracion transepicutanea para el tratamiento del sindrome de las piernas inquietas. |
| PCT/EP2003/004685 WO2003092677A1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
| JP2004500861A JP5253707B2 (ja) | 2002-05-06 | 2003-05-05 | レストレスレッグス症候群を処置するための経外角皮的投与形 |
| CA2483120A CA2483120C (en) | 2002-05-06 | 2003-05-05 | Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome |
| AT03727432T ATE387912T1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
| DK03727432T DK1501499T3 (da) | 2002-05-06 | 2003-05-05 | Transepikutan indgivelsesform til behandling af restless legs-syndromet |
| PL373276A PL218549B1 (pl) | 2002-05-06 | 2003-05-05 | Zastosowanie rotygotyny do wytwarzania leku do przezskórnego leczenia Zespołu Niespokojnych Nóg |
| IL164861A IL164861A (en) | 2002-05-06 | 2004-10-27 | Use of rotigotine for the production of a medicament for treating restless leg syndrome |
| ZA2004/08862A ZA200408862B (en) | 2002-05-06 | 2004-11-02 | Trans epicutaneous administration form for treating restless leg syndrome |
| NO20045240A NO333619B1 (no) | 2002-05-06 | 2004-11-30 | Transepikutan administrasjonsform for a behandle restless leg syndromet |
| CY20081100471T CY1107452T1 (el) | 2002-05-06 | 2008-05-02 | Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων |
| JP2010098924A JP2010159302A (ja) | 2002-05-06 | 2010-04-22 | レストレスレッグス症候群を処置するための経外角皮的投与形 |
| US15/428,614 US20170151215A1 (en) | 2002-05-06 | 2017-02-09 | Use of rotigotine for treating the restless leg syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10220230A DE10220230A1 (de) | 2002-05-06 | 2002-05-06 | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10220230A1 true DE10220230A1 (de) | 2003-11-27 |
Family
ID=29285132
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10220230A Ceased DE10220230A1 (de) | 2002-05-06 | 2002-05-06 | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| DE50309318T Expired - Lifetime DE50309318D1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50309318T Expired - Lifetime DE50309318D1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1501499B1 (enExample) |
| JP (2) | JP5253707B2 (enExample) |
| KR (1) | KR20040104697A (enExample) |
| CN (1) | CN100396281C (enExample) |
| AT (1) | ATE387912T1 (enExample) |
| AU (1) | AU2003233233B2 (enExample) |
| BR (1) | BR0309837A (enExample) |
| CA (2) | CA2483120C (enExample) |
| CY (1) | CY1107452T1 (enExample) |
| DE (2) | DE10220230A1 (enExample) |
| DK (1) | DK1501499T3 (enExample) |
| ES (1) | ES2301795T3 (enExample) |
| IL (2) | IL164861A0 (enExample) |
| MX (1) | MXPA04010687A (enExample) |
| NO (1) | NO333619B1 (enExample) |
| NZ (1) | NZ536533A (enExample) |
| PL (1) | PL218549B1 (enExample) |
| PT (1) | PT1501499E (enExample) |
| RU (1) | RU2301063C9 (enExample) |
| SI (1) | SI1501499T1 (enExample) |
| UA (1) | UA81625C2 (enExample) |
| WO (1) | WO2003092677A1 (enExample) |
| ZA (1) | ZA200408862B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| ES2466647T3 (es) * | 2006-05-08 | 2014-06-10 | Teikoku Seiyaku Co., Ltd. | Preparación absorbible por vía transdérmica que comprende un agente contra la demencia |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| MY165575A (en) | 2007-11-28 | 2018-04-05 | Ucb Pharma Gmbh | Polymorphic form of rotigotine |
| US20110028880A1 (en) | 2008-02-27 | 2011-02-03 | Hisamitsu Pharmaceutical Co., Inc. | Patch |
| JP5546013B2 (ja) | 2008-02-27 | 2014-07-09 | 久光製薬株式会社 | 貼付剤及び包装体 |
| EP2201941A1 (de) | 2008-12-29 | 2010-06-30 | UCB Pharma GmbH | Pflaster-Herstellungstechnologie |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| CN102665699A (zh) | 2009-12-22 | 2012-09-12 | 优时比制药有限公司 | 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮 |
| US8729306B2 (en) | 2010-02-05 | 2014-05-20 | Ucb Pharma Gmbh | Process for the preparation of nitrogen substituted aminotetralins derivatives |
| BR112012029944A2 (pt) | 2010-06-25 | 2019-09-24 | Ucb Pharma Gmbh | processo para preparação de derivados de aminotetralinas substituídas com nitrogênio |
| EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
| WO2013075823A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprising rotigotine and crystallization inhibitor |
| DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
| KR101558042B1 (ko) * | 2012-07-05 | 2015-10-07 | 에스케이케미칼주식회사 | 로티고틴을 함유한 경피흡수제제 |
| EP2870963A4 (en) * | 2012-07-06 | 2016-03-09 | Sk Chemicals Co Ltd | PREPARATION CONTAINING ROTIGOTINE FOR PERCUTANEOUS ABSORBING |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| CA2916183C (en) | 2013-07-03 | 2022-03-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
| MX2016011152A (es) | 2014-02-27 | 2016-12-09 | Medrx Co Ltd | Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa. |
| US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| JP6573913B2 (ja) | 2014-05-20 | 2019-09-11 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ロチゴチンを含む経皮送達システム |
| CA2948219C (en) | 2014-05-20 | 2023-04-04 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| KR102401412B1 (ko) | 2019-06-14 | 2022-05-23 | 히사미쓰 세이야꾸 가부시키가이샤 | 로티고틴 함유 첩부제 |
| FI3854388T3 (fi) | 2020-01-24 | 2023-11-27 | Luye Pharma Switzerland Ag | Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998031362A1 (en) * | 1997-01-17 | 1998-07-23 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
| DE19938825A1 (de) * | 1999-08-19 | 2001-04-26 | Boehringer Ingelheim Pharma | Wirkstoffkombination mit Clonidin |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5232702A (en) * | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
| DE4238223C1 (de) * | 1992-11-12 | 1994-05-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung |
| US5482988A (en) * | 1994-01-14 | 1996-01-09 | Dow Corning Corporation | Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives |
| IL116539A (en) * | 1995-01-06 | 2002-02-10 | Noven Pharma | Preparations given through the skin of unstable anti-acid drugs |
| FR2749514B1 (fr) * | 1996-06-11 | 1998-08-07 | Hoechst Marion Roussel | Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament |
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| ES2203563T3 (es) * | 2001-05-08 | 2004-04-16 | Schwarz Pharma Ag | Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson. |
| DK1256339T3 (da) * | 2001-05-08 | 2004-02-09 | Sanol Arznei Schwarz Gmbh | Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom |
-
2002
- 2002-05-06 DE DE10220230A patent/DE10220230A1/de not_active Ceased
-
2003
- 2003-05-05 RU RU2004131866/15A patent/RU2301063C9/ru active
- 2003-05-05 SI SI200331195T patent/SI1501499T1/sl unknown
- 2003-05-05 CA CA2483120A patent/CA2483120C/en not_active Expired - Fee Related
- 2003-05-05 PT PT03727432T patent/PT1501499E/pt unknown
- 2003-05-05 KR KR10-2004-7017685A patent/KR20040104697A/ko not_active Ceased
- 2003-05-05 WO PCT/EP2003/004685 patent/WO2003092677A1/de not_active Ceased
- 2003-05-05 DE DE50309318T patent/DE50309318D1/de not_active Expired - Lifetime
- 2003-05-05 IL IL16486103A patent/IL164861A0/xx unknown
- 2003-05-05 NZ NZ536533A patent/NZ536533A/en not_active IP Right Cessation
- 2003-05-05 UA UA20041109078A patent/UA81625C2/ru unknown
- 2003-05-05 AT AT03727432T patent/ATE387912T1/de active
- 2003-05-05 PL PL373276A patent/PL218549B1/pl unknown
- 2003-05-05 CN CNB038160250A patent/CN100396281C/zh not_active Expired - Fee Related
- 2003-05-05 CA CA2787384A patent/CA2787384A1/en not_active Abandoned
- 2003-05-05 MX MXPA04010687A patent/MXPA04010687A/es active IP Right Grant
- 2003-05-05 ES ES03727432T patent/ES2301795T3/es not_active Expired - Lifetime
- 2003-05-05 DK DK03727432T patent/DK1501499T3/da active
- 2003-05-05 AU AU2003233233A patent/AU2003233233B2/en not_active Ceased
- 2003-05-05 BR BR0309837-0A patent/BR0309837A/pt not_active Application Discontinuation
- 2003-05-05 EP EP03727432A patent/EP1501499B1/de not_active Revoked
- 2003-05-05 JP JP2004500861A patent/JP5253707B2/ja not_active Expired - Lifetime
-
2004
- 2004-10-27 IL IL164861A patent/IL164861A/en active IP Right Grant
- 2004-11-02 ZA ZA2004/08862A patent/ZA200408862B/en unknown
- 2004-11-30 NO NO20045240A patent/NO333619B1/no not_active IP Right Cessation
-
2008
- 2008-05-02 CY CY20081100471T patent/CY1107452T1/el unknown
-
2010
- 2010-04-22 JP JP2010098924A patent/JP2010159302A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998031362A1 (en) * | 1997-01-17 | 1998-07-23 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
| DE19938825A1 (de) * | 1999-08-19 | 2001-04-26 | Boehringer Ingelheim Pharma | Wirkstoffkombination mit Clonidin |
Non-Patent Citations (1)
| Title |
|---|
| Clinical Pharmacology 24(3), 163-169 (2001) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1501499B1 (de) | Transepikutane darreichungsform zur behandlung des restless leg syndroms | |
| DE60100994T2 (de) | Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson | |
| DE60100595T2 (de) | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson | |
| EP1490052B1 (de) | Vorrichtung zur transdermalen verabreichung von rotigotin-base | |
| EP1033978B1 (de) | D2-agonist enthaltendes transdermales therapeutisches system zur behandlung des parkinson-syndroms und verfahren zu seiner herstellung | |
| DE69530004T2 (de) | Transdermale verabreichung von apomorphin | |
| DE69822199T2 (de) | Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits-/hyperaktivitätsstörungen mit methylphenidat | |
| DE69916492T3 (de) | Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen | |
| DE69528602T2 (de) | Prophylaktische behandlung der allergischen kontaktdermatitis | |
| WO2005011687A1 (de) | Transdermales therapeutisches system mit dem wirkstoff pramipexol | |
| EP1669063A1 (de) | TTS zur Verabreichung von Rotigotin | |
| EP2111857A1 (de) | Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon | |
| EP2797588A1 (de) | Transdermales therapeutisches system mit geringer neigung zur spontankristallisation | |
| DE60309329T2 (de) | Verbessertes transdermales abgabesystem | |
| DE102006019293A1 (de) | Pflaster, enthaltend ein Fentanyl Analogum | |
| EP1171105A1 (de) | Transdermales therapeutisches system mit einem stark wirksamen neuroleptikum | |
| EP3829550B1 (de) | Transdermales therapeutisches system zur abgabe von scopolamin ohne membran | |
| DE112009002721T5 (de) | Antiemetisches Pflaster | |
| WO1994005295A1 (de) | Transdermales therapeutisches system mit pentylentetrazol als wirkstoff | |
| DE112024000733T5 (de) | Transdermales therapeutisches system zur transdermalen verabreichung von huperzin a | |
| DE10318714A1 (de) | Wirkstoff-Kombination und Therapien zur Bekämpfung des Alkoholmissbrauchs | |
| EP2079458A2 (de) | Transdermales therapeutisches system mit zweiphasigem freisetzungsprofil | |
| EP3854388A1 (de) | Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber | |
| DE10301930A1 (de) | Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung | |
| WO2008064815A2 (de) | Zubereitung zur transdermalen verabreichung von galanthamin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8131 | Rejection |